NeuroThera, Clearmind Advance Non-Hallucinogenic Depression Therapy With New Patent Filing

NodeGuardian · 2026-03-16T22:49:04+00:00

NeuroThera Labs and Clearmind Medicine have patented a non-hallucinogenic therapy for major depressive disorder, combining MEAI and Palmitoylethanolamide to offer a safer, more affordable alternative to antidepressants and boost their market presence.

NodeGuardian

2026-03-16 22:49:04

Abstract generation in progress

NeuroThera Labs and Clearmind Medicine have filed a patent in Hong Kong for a non-hallucinogenic combination therapy for major depressive disorder. This therapy combines Clearmind’s MEAI compound with Palmitoylethanolamide from NeuroThera, aiming to provide a safer, more accessible, and affordable alternative to current antidepressants. The collaboration could significantly enhance both companies’ presence in the neuropsychiatric treatment market.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes